Vanguard Group Inc. Has $255.94 Million Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Vanguard Group Inc. increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 0.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,947,640 shares of the biopharmaceutical company’s stock after acquiring an additional 104,444 shares during the period. Vanguard Group Inc. owned about 8.38% of ACADIA Pharmaceuticals worth $255,939,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ACAD. State Street Corp increased its stake in shares of ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after buying an additional 173,084 shares during the period. Geode Capital Management LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 1.1% during the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock worth $44,234,000 after purchasing an additional 30,826 shares during the period. SG Americas Securities LLC increased its holdings in ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the period. Great Lakes Advisors LLC acquired a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at $9,909,000. Finally, Burney Co. acquired a new position in ACADIA Pharmaceuticals during the 4th quarter worth about $6,953,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 4.6 %

Shares of ACADIA Pharmaceuticals stock opened at $15.38 on Friday. ACADIA Pharmaceuticals Inc. has a 52 week low of $14.15 and a 52 week high of $20.68. The business has a 50 day moving average price of $18.14 and a 200-day moving average price of $17.04. The company has a market cap of $2.57 billion, a PE ratio of 19.72 and a beta of 0.54.

Insider Buying and Selling

In other news, EVP Mark C. Schneyer sold 3,171 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total value of $54,065.55. Following the completion of the transaction, the executive vice president now directly owns 56,889 shares of the company’s stock, valued at $969,957.45. This represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.85 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,433 shares of company stock worth $187,319. 28.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on ACAD shares. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Morgan Stanley restated an “equal weight” rating and issued a $20.00 target price on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, ACADIA Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $23.93.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.